Last reviewed · How we verify
Polysporin Ointment
Polysporin Ointment combines two antibiotics (bacitracin and polymyxin B) that work synergistically to inhibit bacterial cell wall synthesis and disrupt cell membrane integrity.
Polysporin Ointment combines two antibiotics (bacitracin and polymyxin B) that work synergistically to inhibit bacterial cell wall synthesis and disrupt cell membrane integrity. Used for Minor cuts, scrapes, and wounds, Prevention of infection in minor skin injuries, Topical treatment of minor bacterial skin infections.
At a glance
| Generic name | Polysporin Ointment |
|---|---|
| Also known as | Polysporin, Bacitracin |
| Sponsor | University of British Columbia |
| Drug class | Topical antibiotic combination |
| Target | Bacterial cell wall (bacitracin) and bacterial cell membrane (polymyxin B) |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Bacitracin inhibits bacterial cell wall synthesis by blocking dephosphorylation of lipid carriers essential for peptidoglycan formation. Polymyxin B disrupts bacterial cell membranes by binding to lipopolysaccharides and causing leakage of cellular contents. Together, these agents provide broad-spectrum coverage against gram-positive and gram-negative bacteria commonly found in skin infections.
Approved indications
- Minor cuts, scrapes, and wounds
- Prevention of infection in minor skin injuries
- Topical treatment of minor bacterial skin infections
Common side effects
- Local irritation or rash
- Allergic contact dermatitis
- Itching or burning at application site
Key clinical trials
- A Between Patient Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries (PHASE1, PHASE2)
- A Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries (PHASE1, PHASE2)
- Topical Antibiotic Prophylaxis for Eyelids (PHASE4)
- Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy (PHASE4)
- Tacrolimus for Malar Edema (PHASE2, PHASE3)
- Heparin for the Treatment of Burn Wound Pain (NA)
- Topical Antibiotics for Prevention of Intensive Care Unit (ICU) Central Line Infections (NA)
- Use of Ointments in Prevention of Catheter Related Infections in PD (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Polysporin Ointment CI brief — competitive landscape report
- Polysporin Ointment updates RSS · CI watch RSS
- University of British Columbia portfolio CI